Kyverna Therapeutics (NASDAQ:KYTX) Posts Quarterly Earnings Results, Hits Estimates

Kyverna Therapeutics (NASDAQ:KYTX) posted its earnings results on Thursday. The company reported ($0.68) earnings per share for the quarter, meeting the consensus estimate of ($0.68), FiscalAI reports.

Kyverna Therapeutics Stock Down 1.8%

Kyverna Therapeutics stock traded down $0.09 during midday trading on Thursday, hitting $5.03. 1,198,533 shares of the stock were exchanged, compared to its average volume of 806,677. Kyverna Therapeutics has a 1 year low of $4.49 and a 1 year high of $13.67. The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06. The company has a 50 day moving average price of $6.28 and a two-hundred day moving average price of $7.90.

Analysts Set New Price Targets

Several research analysts have commented on KYTX shares. Benchmark reissued a “buy” rating on shares of Kyverna Therapeutics in a research report on Friday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, September 21st. William Blair upgraded Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating on shares of Kyverna Therapeutics in a research note on Thursday, October 22nd. Finally, Needham & Company LLC set a $25.00 target price on Kyverna Therapeutics in a report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.00.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.